Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 8/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.45 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29624091 | 1.00 | TGFBR1 (0.61) | TGFBR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6975683 | 0.94 | TGFBR1 (0.54) | TGFBR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6966236 | 0.92 | TGFBR1 (0.54) | TGFBR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6179707 | 0.88 | TGFBR1 (0.50) | TGFBR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6979584 | 0.86 | TGFBR1 (0.45) | TGFBR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4075747 | 0.80 | MEN1 (0.46) | TGFBR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7552634 | 0.79 | TGFBR1 (0.60) | TGFBR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7553394 | 0.79 | TGFBR1 (0.60) | TGFBR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL373802 | 0.76 | TGFBR1 (1.00) | TGFBR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL13218171 | 0.76 | ATM (0.43) | TGFBR1MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009047163-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-16 | — | — | WO | claimed |
| US-20090099237-A1 | Methods of treating inflammatory diseases | ROCHE PALO ALTO LLC | 2009-04-16 | — | — | US | claimed |
| US-20080146617-A1 | Methods of treating inflammatory diseases | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | claimed |
| WO-2008071605-A2 | METHODS OF TREATING INFLAMMATORY DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | WO | claimed |
| EP-1771171-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | Schering-Plough Ltd. (CH) | 2007-04-11 | — | — | EP | claimed |
| US-20060194845-A1 | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | SCHERING CORPORATION | 2006-08-31 | — | — | US | claimed |
| WO-2006025988-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | SCHERING-PLOUGH LTD. (CH) | 2006-03-09 | — | — | WO | claimed |
| EP-1169317-B1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | claimed |
| US-6465493-B1 | SUCH AS 4-(4-(4-FLUOROPHENYL)-5-(2-PYRIDYL)-1-HYDROXY-1H-IMIDAZOL-2-YL)BENZONITRILE; ALK5 MEDIATED DISEASES SUCH AS ARTHRITIS, OSTEOPOROSIS, KIDNEY AND RENAL DISEASES, CONGES-TIVE HEART FAILURE, ULCERS, DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM CORPORATION | 2002-10-15 | — | — | US | claimed |
| US-20240084258-A1 | METHOD FOR PREPARING BROWN ADIPOCYTE | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2024-03-14 | — | — | US | disclosed |
| EP-3133149-B1 | METHOD FOR PREPARING OSTEOBLASTS AND OSTEOBLAST INDUCER | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2022-06-22 | — | — | EP | disclosed |
| US-11174464-B2 | Method for preparing osteoblasts and osteoblast inducer | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2021-11-16 | — | — | US | disclosed |
| CN-106459903-B | Preparation method of osteoblast and osteoblast inducer | 京都府公立大学法人 | 2021-04-23 | — | — | CN | disclosed |
| US-20180355319-A1 | METHOD FOR PREPARING BROWN ADIPOCYTE | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2018-12-13 | — | — | US | disclosed |
| US-20060194845-A1 | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | SCHERING CORPORATION | 2006-08-31 | — | — | US | disclosed |
| WO-2006025988-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | SCHERING-PLOUGH LTD. (CH) | 2006-03-09 | — | — | WO | disclosed |
| EP-1169317-B1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | disclosed |
| US-6465493-B1 | SUCH AS 4-(4-(4-FLUOROPHENYL)-5-(2-PYRIDYL)-1-HYDROXY-1H-IMIDAZOL-2-YL)BENZONITRILE; ALK5 MEDIATED DISEASES SUCH AS ARTHRITIS, OSTEOPOROSIS, KIDNEY AND RENAL DISEASES, CONGES-TIVE HEART FAILURE, ULCERS, DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM CORPORATION | 2002-10-15 | — | — | US | disclosed |
| EP-1169317-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061576-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194845-A1 | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | ALK, ACVR1, MSTN | TGFBR1 56/4885MAPK13 1750/4885MAPK12 1902/4885 |
| US-11174464-B2 | Method for preparing osteoblasts and osteoblast inducer | CKMT1A; CKMT1B, PACSIN2, SREBF1 | TGFBR1 1614/4885MAPK13 956/4885MAPK12 1120/4885 |
| US-20240084258-A1 | METHOD FOR PREPARING BROWN ADIPOCYTE | FABP4, MAPK1, MAP3K1 | TGFBR1 304/4885MAPK13 50/4885MAPK12 44/4885 |
| US-20090099237-A1 | Methods of treating inflammatory diseases | CSNK1A1, PACSIN2, CSNK1G1 | TGFBR1 3096/4885MAPK13 793/4885MAPK12 1222/4885 |
| US-20080146617-A1 | Methods of treating inflammatory diseases | CSNK1A1, PACSIN2, CSNK1G1 | TGFBR1 3096/4885MAPK13 793/4885MAPK12 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.